19
Views
2
CrossRef citations to date
0
Altmetric
Prostate

Clinicopathological features of prostate cancers detected after an initial diagnosis of ‘atypical glands suspicious for cancer’

&
Pages 334-338 | Published online: 04 May 2010

References

  • Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006; 175: 820–834.
  • Cheville JC, Reznicek MJ, Bostwick DG. The focus of ‘atypical glands, suspicious for malignancy’ in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. Am J Clin Pathol 1997; 108: 633–640.
  • Schlesinger C, Bostwick DG, Iczkowski KA. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice. Am J Surg Pathol 2005; 29: 1201–1207.
  • Bostwick DG, Meiers I. Atypical small acinar proliferation in the prostate: clinical significance in 2006. Arch Pathol Lab Med 2006; 130: 952–957.
  • Brausi M, Castagnetti G, Dotti A, et al Immediate radical prostatectomy in patients with atypical small acinar proliferation. Over treatment? J Urol 2004; 172: 906–908; discussion 908–9.
  • Iczkowski KA, Chen HM, Yang XJ, Beach RA. Prostate cancer diagnosed after initial biopsy with atypical small acinar proliferation suspicious for malignancy is similar to cancer found on initial biopsy. Urology 2002; 60: 851–854.
  • Renshaw AA, Santis WF, Richie JP. Clinicopathological characteristics of prostatic adenocarcinoma in men with atypical prostate needle biopsies. J Urol 1998; 159: 2018–2021; discussion 2022.
  • Mallen E, Gil P, Sancho C, et al Atypical small acinar proliferation: review of a series of 64 patients. Scand J Urol Nephrol 2006; 40: 272–275.
  • Renshaw AA, Chang H, D'Amico AV. Estimation of tumor volume in radical prostatectomy specimens in routine clinical practice. Am J Clin Pathol 1997; 107: 704–708.
  • Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol 1997; 157: 2206–2209.
  • Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368–374.
  • Thorson P, Humphrey PA. Minimal adenocarcinoma in prostate needle biopsy tissue. Am J Clin Pathol 2000; 114: 896–909.
  • Shah RB, Zhou M, LeBlanc M, et al Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 2002; 26: 1161–1168.
  • Zhou M, Aydin H, Kanane H, Epstein JI. How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol 2004; 28: 239–243.
  • Chan TY, Epstein JI. Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology 1999; 53: 351–355.
  • Ellis WJ, Brawer MK. Repeat prostate needle biopsy: who needs it? J Urol 1995; 153: 1496–1498.
  • Iczkowski KA, MacLennan GT, Bostwick DG. Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases. Am J Surg Pathol 1997; 21: 1489–1495.
  • Rubin MA, Bismar TA, Curtis S, Montie JE. Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients? Am J Surg Pathol 2004; 28: 946–952.
  • Descazeaud A, Rubin MA, Allory Y, et al What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer? Eur Urol 2005; 48: 911–915.
  • Fadare O, Wang S, Mariappan MR. Practice patterns of clinicians following isolated diagnoses of atypical small acinar proliferation on prostate biopsy specimens. Arch Pathol Lab Med 2004; 128: 557–560.
  • Stamey TA, Freiha FS, McNeal JE, et al Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71: 933–938.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.